All In Biotech

Drug Trial Radar · NCT06627413

Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder

A Phase 1b, Open-label Study to Determine the Pharmacokinetics, Safety, and Tolerability of Single, Ascending Doses of Lumateperone Long-acting Injectable Formulations Administered Intramuscularly to Patients With Schizophrenia or Schizoaffective Disorder

Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Aug 23, 2024

Primary completion

Nov 20, 2025

Study completion Nov 20, 2025

Sponsor

Lead sponsor
Intra-Cellular Therapies, Inc.Industry
Sponsor type
Industry
First posted
Oct 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study ITI-007-037 is a Phase 1b, open-label study to evaluate the safety, tolerability, and PK of lumateperone long-acting injectable (LAI) formulations after a single intramuscular injection in patients with stale schizophrenia or schizoaffective disorder.

Conditions

  • Schizophrenia or Schizoaffective

Interventions

  • Lumateperone CapsuleDrug

    Lumateperone 42 mg capsule, oral administration

  • Lumateperone LAIDrug

    Lumateperone LAI X500-E2 IM injection

  • Lumateperone LAIDrug

    Lumateperone LAI X500-E3 IM injection

  • Lumateperone LAIDrug

    Lumateperone LAI X500-X2 IM injection

  • Lumateperone LAIDrug

    Lumateperone LAI X500-X5 IM injection

  • Lumateperone LAIDrug

    Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics: Cmax,oralTime frame: Day 5
  2. Pharmacokinetics: Cmax,IMTime frame: Day 11-60
  3. Pharmacokinetics: Tmax,oralTime frame: Day 5
  4. Pharmacokinetics: Tmax,IMTime frame: Day 11-60
  5. Pharmacokinetics: AUC0-t,oralTime frame: Day 5
  6. Pharmacokinetics: AUC0-t,IMTime frame: Day 11-60

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Collaborative Neuroscience Research, LLC

    Los Alamitos, California

  • CenExeli Research LLC

    Atlanta, Georgia

  • Atlanta Center for Medical Research

    Atlanta, Georgia

  • Hassman Research Institute, LLC.

    Marlton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.